Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5224_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Contents
- •Outcome Evaluation
- •Introduction
- •Clinical Presentation of Muscular Weakness in the Critical Patients
- •Critical Illness Polyneuropathy (CIP) and Critical Illness Myopathy (CIM)
- •Ventilator-Induced Diaphragmatic Dysfunction (VIDD)
- •Dysphagia, Swallowing, and Effective Cough
- •The Pathophysiology of Acute Skeletal Muscle Wasting
- •Risk Factors
- •Short-Term and Long-Term Outcome
- •Conclusions
- •References
- •Introduction
- •The Neuroendocrine Response
- •Pathophysiology of Stress Response
- •The Hypothalamus-Pituitary-Adrenal (HPA) Axis
- •GH Axis
- •Pituitary-Thyroid Axis
- •Pituitary-Adrenal Axis
- •Mitochondrial Dysfunction
- •Metabolic Aspects of Stress Response
- •Conclusion
- •References
- •Introduction
- •Disorders of Fluid Balance
- •Dysionemias
- •Dysnatremias
- •Dyskalemias
- •Other Electrolyte Derangements (Calcium, Magnesium, Phosphorus)
- •Alterations of Acid Base Balance
- •Acid-Base Disturbances
- •Metabolic Acidosis
- •Respiratory Acidosis
- •Metabolic Alkalosis
- •Respiratory Alkalosis
- •Conclusion
- •References
- •Introduction
- •Epidemiology and Risk Factors
- •Diagnosis
- •Differential Diagnosis
- •Treatment
- •Prognosis
- •Future Perspectives
- •References
- •Introduction
- •Gut Microbiome
- •Gut-Organ Axis
- •Gut-Lung Axis
- •ICU Dysbiosis
- •Gut Changes
- •Microbial Therapy in ICU
- •Antimicrobial Stewardship
- •Nutrition as a Key Factor for Gut Microbiome Homeostasis
- •Probiotics, Prebiotics, and Synbiotics
- •Fecal Microbiota Transplantation
- •Conclusion
- •References
- •Introduction
- •Validation Process
- •Screening Tools Overview
- •Discussion
- •Conclusion
- •References
- •Introduction
- •Fight-and-Flight Reaction
- •Calorimetry and Total Energy Expenditure
- •Role of Mitochondria in the Various Stages of Intensive Care Recovery
- •REE in Different Clinical Scenarios
- •Conclusions
- •References
- •Introduction
- •Nutrition in ICU: Evidence from RCTs
- •Inclusion of Too Many Patients Considered at Low Nutritional Risk
- •Unfavorable Energy to Protein Doses
- •Absence of Indirect Calorimetry-Guided Energy Dosing
- •Anabolic Resistance
- •Suppression of Fasting-Induced Recovery Pathways
- •Future Perspectives
- •Development and Validation of Tools to Guide Individualized Nutritional Support
- •Implications for Clinical Practice
- •Conclusion
- •References
- •Introduction
- •Protein Metabolism in Critical Illness
- •Protein Requirements and Current Evidence
- •Timing of Introduction
- •Early mobilization, Exercise, and Adjuvant Therapies
- •Conclusion
- •References
- •Introduction
- •Computed Tomography Scan
- •Bioelectrical Impedance Analysis
- •Musculoskeletal Ultrasound
- •Respiratory Muscle Ultrasound
- •Limb Muscles
- •Conclusions
- •References
- •Functional Principles
- •Hydration Status Evaluations in Critically Ill Patients
- •Body Composition and Nutrition in ICU
- •Limits of BIVA in Critically Ill Patients
- •Conclusions
- •References
- •Introduction
- •Introduction
- •Historical Perspective
- •Enteral Versus Parenteral Nutrition Nowadays
- •Conclusions
- •References
- •Enteral Nutrition
- •Components of Enteral Mixtures
- •Choice of the Enteral Mixture
- •Special Composition Formulas
- •Conclusions
- •References
- •Introduction
- •Complications Related to Enteral Feeding Tubes
- •Aspiration
- •Gastrointestinal Intolerance
- •Diarrhea
- •New Horizons
- •New Technologies to Prevent Enteral Nutrition Complications
- •Advanced Tube Feedings
- •smART Platform
- •Conclusions
- •References
- •Introduction
- •Composition of PN Admixtures
- •Energetic Substrates
- •Carbohydrates
- •Lipid Emulsions
- •Proteins
- •Micronutrients: Electrolytes, Vitamins, and Trace Elements
- •Types of Parenteral Nutrition
- •Compatibility and Stability of the Parenteral Nutrition
- •References
- •Introduction
- •Metabolic Complications
- •Hyperglycemia
- •Hypertriglyceridemia
- •Liver Disease: Steatosis, Cholestatic Disease, and Gallbladder Stones
- •Refeeding Syndrome
- •Mechanical Complications
- •Infectious Complications
- •Conclusions
- •References
- •Introduction
- •Macronutrients
- •Glutamine
- •Arginine
- •Leucine
- •ω-3 Fatty Acids
- •Micronutrients
- •Antioxidant Vitamins
- •Antioxidant Trace Elements
- •Probiotics, Prebiotics or Symbiotics
- •Use of Probiotics in Clinical Practice?
- •References
- •Introduction
- •Pathophysiological Mechanisms, Risk Factors, and Clinical Implications
- •Pathophysiological Mechanisms of ICUAW
- •Risk Factors Associated with Physical and Functional Recovery in Critically Ill Patients
- •Clinical Impact of Poor Physical and Functional Recovery in Critical Illnesses
- •How to Assess Physical and Functional Recovery in Critical Illnesses
- •Management and Therapies
- •Nutritional Therapy
- •Other Supportive Therapies
- •Patient- and Family-centered ICU Environment
- •Conclusions
- •References
- •Bioethics in Clinical Practices
- •Ethical Consideration on Nutrition
- •Conclusion
- •References
- •Introduction
- •Nutrition in ARDS
- •Caloric Goals
- •Diet Composition
- •Immunonutrition
- •Oral Versus Enteral Versus Parenteral Nutrition
- •Nutrition in COVID-19 Respiratory Failure
- •Nutrition in ECMO Support
- •Enteral Nutrition
- •Parenteral Nutrition
- •Nutritional Goals
- •Conclusions
- •References
- •Introduction
- •Timing and Route of Nutritional Support
- •Initial Assessment of the Burn Patient
- •Estimation of Energy Expenditure
- •Macronutrients and Micronutrients
- •Proteins
- •Carbohydrates
- •Immunonutrients
- •Arginine
- •Nucleotides
- •ω3 Fatty Acids
- •Glutamine
- •Monitoring of Nutritional Support
- •Nutritional Support for Trauma Patients
- •Route of Feeding: Digestive Tract (Enteral Nutrition) Versus Intravenous (Parenteral Nutrition)
- •Standard or Immune-Enhancing Enteral Nutrition
- •Estimation or Measurement of Energy Requirements
- •Macronutrients
- •Conclusions
- •References
- •Introduction
- •General Considerations
- •Assessment of Nutritional Needs
- •Metabolic Changes Induced by Sepsis, AKI, and CRRT
- •Protein Metabolism
- •Lipid Metabolism
- •Vitamins and Trace Elements
- •Phosphates
- •Approaches to Nutrition
- •Enteral
- •Parenteral
- •Timing
- •Recommendations
- •Conclusion
- •References
- •Introduction
- •Acute Liver Failure
- •Nutrition in ALF
- •Acute Pancreatitis
- •IAP Management
- •Conclusions
- •References
- •Introduction
- •Nutritional Considerations in Major Surgery
- •Nutritional Requirements During and After Major Surgery
- •Challenges in Meeting Nutritional Needs Post-Surgery
- •Strategies for Enhancing Nutritional Intake and Absorption
- •Intestinal Failure: Nutritional Challenges and Management
- •Impact of Intestinal Failure on Nutritional Status
- •Nutritional Management Strategies for Patients with Intestinal Failure
- •Role of Parenteral Nutrition and Enteral Nutrition in Intestinal Failure Cases
- •Open Abdomen: Nutritional Support and Wound Healing
- •Nutritional Requirements for Patients with Open Abdomen Wounds
- •Challenges in Providing Nutritional Support to Patients with Open Abdomen
- •Clinical Protocols and Guidelines for Nutritional Support
- •Conclusions
- •References
- •Introduction
- •Nutrition Therapy
- •Determination of Energy Expenditure
- •Route and Timing of Enteral Nutrition
- •Intolerance to Enteral Nutrition
- •Brain Energy Metabolism and Energy Dysfunction Following Acute Brain Injury
- •In Vivo Brain Energy and Glucose Monitoring
- •Alternative Energy Substrates
- •Lactate
- •Ketone Bodies
- •Immunonutrition and Micronutrients
- •Conclusions and Future Directions
- •References
- •Introduction
- •AKI and Cardiac Surgery
- •AKI and Vascular Surgery
- •AKI and Sepsis
- •AKI and Surgery
- •Trauma
- •Burn
- •AKI and COVID-19
- •Conclusion
- •References
- •Introduction
- •AKI Etiology
- •Subclinical AKI and AKI Biomarkers
- •Subphenotyping AKI
- •Conclusions
- •References
- •Introduction
- •What Are Biomarkers?
- •Novel Biomarkers: How Can They be Implemented?
- •Biomarkers for the Prediction of AKI and Detection of Subclinical Stages
- •Postoperative Biomarker-Guided Prevention of AKI in Patients at High Risk
- •Biomarkers for Other Indications
- •Conclusion
- •References
- •Introduction
- •The Machine Learning Arena
- •The Challenges of Timely Prediction of Acute Kidney Injury
- •Early Machine Learning Models for AKI Prediction
- •New Techniques for AKI Prediction Using Deep Learning ML Models
- •Clinical Decision Support Systems
- •The Translational Research Gap and the Value of Data Sharing: A Plea for Data Sharing
- •Limitations of Machine Learning Models
- •Conclusions
- •References
- •Introduction
- •Doppler Assesses Vascular Congestion
- •Arterial Renal Doppler Ultrasound in AKI
- •Integration of Renal Resistive Index and Intrarenal Venous Flow
- •Contrast-Enhanced Ultrasound for Assessing Renal Perfusion
- •Conclusions
- •References
- •Introduction
- •Renal Perfusion and Goals of Fluids in AKI
- •Clinical Evaluation of a Patient with AKI in ICU
- •Studies Which Investigated the Association of Fluid Therapy and AKI
- •Volume of Fluid
- •Type of Fluid
- •Crystalloids
- •Colloids
- •Starches
- •Gelatins
- •Conclusion
- •References
- •Introduction
- •Pathophysiology of Renal Perfusion
- •Acute Kidney Injury
- •Norepinephrine
- •Epinephrine
- •Dopamine
- •Vasopressin
- •Terlipressin
- •Angiotensin II
- •Conclusions
- •References
- •Introduction
- •Pharmacology of Diuretics
- •Loop Diuretics
- •Other Classes of Diuretics
- •Indications for Diuretics in AKI
- •Control of Fluid Overload
- •AKI Prognostication
- •Situations in Which Diuretics Are Not Indicated
- •AKI Recovery
- •How to Use Diuretics in the ICU
- •Class and Dose Selection
- •Modality of Loop Diuretic Administration
- •Conclusions
- •References
- •Introduction
- •What Is Acute Kidney Disease?
- •Clinical Course of AKD Within the ICU
- •Management of AKD in Critical Care and Beyond
- •Conclusions and Future Directions
- •References
- •Introduction
- •Renal Functional Reserve
- •Renal Functional Reserve and Renal Recovery After Acute Kidney Injury
- •Conclusion
- •References
- •Background
- •Membrane and Filter Characteristics
- •Geometric Characteristics
- •Performance Characteristics
- •Mechanisms of Fluid and Solute Transport
- •Treatment Modalities
- •Treatment Dose
- •Nomenclature of Renal Replacement Therapies
- •Continuous Therapies
- •Intermittent Therapies
- •Hybrid Therapies
- •Conclusion
- •References
- •Introduction
- •Dialysis Catheters: Technical Aspects
- •Selection of the Site for Dialysis
- •Catheter Insertion Technique
- •Dialysis Catheter Complications
- •Dialysis Catheter Maintenance
- •Conclusions
- •References
- •Introduction
- •Non-pharmacological Strategies to Reduce Membrane Fouling
- •Pharmacological Strategies to Reduce Membrane Clotting
- •Unfractionated Heparin (UFH) Systemic Anticoagulation
- •Systemic Anticoagulation with Low Molecular Weight Heparin (LMWH)
- •Regional Citrate Anticoagulation (RCA)
- •Systemic Anticoagulation with Direct Thrombin Antagonists
- •Nafamostat
- •Conclusions
- •References
- •Introduction
- •CRRT Dose/Outcome Studies: Consideration of Solute Kinetics
- •CRRT Dose as a Quality Criterion
- •CRRT Dose in the Context of Therapy Quality
- •Conclusions
- •References
- •Introduction
- •Patient Selection and Indications for Starting RRT
- •Strategies to Identify Need for RRT
- •Rationale for an Early Strategy to Starting RRT
- •Rationale for a Conservative Strategy to Starting RRT
- •RRT Replacement Therapy and Clinical Outcomes
- •Current Clinical Practice Guideline Recommendations
- •Clinical Trial Evidence on Timing of Starting RRT
- •Implications for Practice
- •Existing Knowledge Gaps and Future Research
- •Conclusions
- •References
- •Introduction
- •Early ICU Phase before KRT
- •Nutrition Care
- •Monitoring
- •ICU Phase with KRT
- •Gains and Losses During CRRT
- •Electrolyte Loss in CRRT
- •Macronutrient Loss in CRRT
- •Macronutrient Gain in CRRT
- •Micronutrients and Vitamin Loss in CRRT
- •Management of Losses During CRRT
- •Monitoring During CRRT
- •Indirect Calorimetry During CRRT
- •ICU Phase After CRRT
- •EN and PN Product Selection
- •Conclusions
- •References
- •Introduction
- •Nomenclature
- •Continuous Therapies
- •Intermittent Renal Replacement Therapies (IRRTs)
- •Hybrid Therapies
- •Technical Aspects of RRT Techniques
- •Hemodynamic Stability
- •Solute Clearance
- •Fluid Balance
- •Vascular Access
- •Anticoagulation
- •Drug Dosing
- •Patient Mobilization
- •The Process of RRT Prescription and Administration
- •Indications of RRT
- •Timing
- •Prescription Parameters
- •Dosing
- •Membrane Choice
- •Dialysate and Reinfusion Solutions
- •Limitations of RRT in Critical Care
- •Patient Safety During RRT in Critical Care
- •Introduction
- •Steps in RRT Management and Protocol Application

86 C. Lauwers et al.
Table 8.1 Suggested mechanisms explaining lack of benefit of early full nutrition in RCTs
Suggested mechanism Supporting evidence?
Without supportive evidence
Inclusion of too many patients considered at low nutritional risk
Unfavorable energy to protein dose No.
Absence of indirect calorimetryguided energy dosing
With supportive evidence
Anabolic resistance Yes.
Suppression of autophagy Yes.
Suppression of ketogenesis Yes.
RCT randomized controlled trial
No.
No subgroup differences in RCTs.
No validated biomarker that can identify patients
benefiting from early full nutritional support
No benefit and potential harm by high-dose proteins
in RCTs.
No.
No benefit of indirect calorimetry- vs. calculation-based
energy dosing in RCTs.
Endogenous energy suppression (not quantified) cannot
be fully suppressed by artificial nutrition.
No prevention of muscle wasting by
in RCTs.
Increased ureagenesis by increased amino acid doses,
suggesting futile catabolism of provided amino acids.
Suppression of autophagy in muscle of patients receiving
early full nutrition, associating with more muscle weakness.
Suppression of autophagy in muscle and vital organs of
critically ill animals receiving early full nutrition, associating with muscle degeneration and poor organ
function.
Suppression of
part explaining harm by early full nutrition.
Exogenous ketone supplements protected critically ill
animals against muscle weakness.
ketogenesis in
early full
critically ill patients, in
nutrition
total study population, supporting dose-dependent harm by early nutritional support
3]. Also, in a secondary analysis of the PermiT RCT that extensively studied
[
potential nutritional risk markers, no marker could identify patients who benefited
from early full nutritional support [28]. Whether novel nutritional risk markers may
discriminate which patients would benefit from early full feeding requires further
study [29]. However, in the absence of new evidence, one should be cautious.
Unfavorable Energy to Protein Doses
Experts have advocated that patients in recent feeding RCTs may have received too
low amino acid doses, and too high glucose and lipid doses [
22]. However, RCTs

8 The Energy Intake: How Much, and at What Time? 87
that specifically studied protein supplements in critically ill patients have not shown
benefit by increased protein doses, and even suggested potential harm. Indeed, in the
EFFORT RCT (N = 1329), high-dose protein (target 2.2 g/kg/d; prescribed
1.6 ± 0.5 g/kg/d) did not improve outcome as compared with standard care (target
1.2 g/kg/d; prescribed 0.9 ± 0.3 g/kg/d) in mechanically ventilated critically ill
patients [
failure scores, high-dose protein even associated with harm [
Nephro-Protective RCT (N = 474), amino acid supplements up to maximum 2 g/
kg/d did not improve outcome, with a trend toward increased use of renal replacement therapy [31]. These RCT data do not support early high-dose protein in critical
illness. These findings are corroborated by secondary analyses of the EPaNIC and
PEPaNIC RCTs that attributed harm by early parenteral nutrition to the increased
amino acid dose rather than to increased glucose or lipid doses [
30]. In patients with acute kidney injury and in patients with high organ
30]. A
lso, in the
13, 14].
Absence of Indirect Calorimetry-Guided Energy Dosing
Recent large feeding RCTs have been criticized for the use of predictive equations to
guide energy dosing [25]. Numerous observational studies have shown that predictive equations only give an imprecise estimation of energy expenditure, as measured
by indirect calorimetry [25]. However, large RCTs have not shown clear benefitof
indirect calorimetry-based energy dosing as compared with calculation-based energy
dosing [32, 33]. Moreover, equaling measured energy expenditure with the energy
target builds on the assumption that all endogenous energy substrate production can
be counteracted by providing nutrients [26]. Especially in the acute phase of critical
illness, this assumption is not valid, however, and the time when endogenous
substrate production is fully suppressible by feeding remains unclear, as outlined
below. Moreover, the largest RCT studying indirect calorimetry-based versus
calculation-based energy dosing, the TICACOS-International RCT (N = 417) may
question the feasibility of routine use of indirect calorimetry, since the RCT was
stopped prematurely because of insufficient patient recruitment after 6 years in
7 expert centers [33, 34]. Moreover, of 417 patients in the intention-to-treat population, indirect calorimetry-based feeding was performed in only 332 patients [33].
Anabolic Resistance
The primary aim of providing nutrition is to avoid critical illness-associated catabolism, which leads to muscle wasting and weakness and is associated with poor
outcomes. However, acute critical illness is characterized by anabolic resistance
[35], as also confirmed by recent RCTs [13, 36]. Muscle proteolysis, which provides
substrate for hepatic gluconeogenesis, seems mainly driven by the endocrine and
inflammatory alterations accompanying acute critical illnesses [
26].
RCTs have

88 C. Lauwers et al.
shown that these processes cannot be counte racted by providing early full nutritional
support [13, 36]. Indeed, providing higher doses of amino acids in the acute phase of
illness through early parenteral nutrition or amino acid supplements uniformly
increased urea concentrations in critically ill patients, suggesting that a large fraction
of the extra amino acids is not incorporated into protein but degraded [14, 30, 31,
37–39]. In the EPaNIC RCT, it was estimated that almost two thirds of the extra
provided amino acids through early parenteral nutrition were net wasted into
ureagenesis [
cally important, as it statistically explained the increased need for renal replacement
therapy [37]. Concomitantly, there was no prevention of microscopic or macroscopic muscle loss, and muscle weakness was even more prevalent in patients
receiving early parenteral nutrition, which may be explained by suppression of
muscle repair pathways, as outlined below [13, 36]. Importantly, early indirect
calorimetry-based feeding—as discussed above—does not consider endogenous
substrate production that is not always suppressible by exogenous nutrients
40]. Hence, indirect calorimetry-based feeding may lead to overfeeding if measured
[
energy expenditure is set as the energy target [26]. Since the extent of insuppressible
endogenous energy production cannot be quantified, indirect calorimetry-based
feeding may theoretically introduce its’ own methodological inaccuracy, just like
calculated energy dosing, especially in acutely ill patients. Also, the time point when
anabolic resistance turns into feeding responsiveness, with suppressible muscle
catabolism and gluconeogenesis, indicating feeding readiness cannot be predicted
or monitor
based feeding may be valuable in the recovery phase of critical illness, allowing to
avoid overfeeding and underfeeding. However, RCTs studying the impact of indirect
calorimetry-based feeding initiated after the first week in ICU and extended into the
recovery phase are lacking.
37]. Feeding-induced increased ureagenesis may have been clini-
ed, and likely varies between patients [26]. In theory, indirect calorimetry-
Suppression of Fasting-Induced Recovery Pathways
Apart from anabolic resistance, the lack of benefit from early feeding may be
explained by the suppression of fasting-induced benefits [26]. Indeed, although
fasting has been regarded as a negative phenomenon in critical illness, recent
evidence suggests that the fasting response may be adaptive to some extent.
Prolonged fasting powerfully activates autophagy and ketogenesis, which may
enhance recovery from a critical insult [41]. Autophagy is a housekeeping process
that removes damaged organelles, intracellular microorganisms, and potentially
toxic protein aggregates, among others [42, 43]. The process is powerfully inhibited
by providing macronutrients, and mechanistic studies have shown that active
autophagy is essential to recover from critical insults [44]. Mechanistic studies
have shown that early parenteral nutrition-induced autophagy suppression was associated with poor muscle and organ function in critically ill patients and animals
[36, 45]. Likewise, fasting activates the generation of ketones, which may stimulate

8 The Energy Intake: How Much, and at What Time? 89
autophagy and have been implicated in muscle regeneration pathways [41]. Mechanistic studies have shown that the protective effects of withholding early parenteral
nutrition may partly be explained by increased ketogenesis [46, 47]. Moreover,
exogenous administration of ketones protected critically ill mice against muscle
weakness [48].
Future Perspectives
Exploiting Fasting-Induced Benefits While Avoiding
Prolonged Starvation
Although the fasting response has been associated with the activation of beneficial
repair pathways in critical illness, prolonged starvation will likely come at the price
of devastating sarcopenia and muscle weakness. Therefore, current guidelines recommend to administer full feeding from the second week in the ICU at the latest
[49]. However, also in patients with prolonged critical illness and persistent organ
failure, repair pathways, including autophagy, are likely important. Yet, the efficacy
and safety of macronutrient restriction beyond the first week in ICU have not been
studied, and continued starvation for weeks is obviously unwanted. Future studies
should investigate whether alternative feeding strategies could activate fasting
responses while avoiding prolonged starvation and whether this is clinically superior. In this regard, fasting responses have also been implicated in protection against
age-related disease [50]. In this context, the beneficial effects of caloric restriction
have been replicated by so-called fasting-mimicking diets [50]. In critical illness,
candidate alternative feeding strategies are intermittent fasting, ketogenic diets, or
ketone supplementation [
mount a fasting response and associated benefits in critically ill patients
remains unclear. A pilot crossover RCT (N = 70) showed that 12 h of fasting
induced a metabolic fasting response with increased ketogenesis in prolonged
critically ill patients, although autophagy activation in white blood cells was unaffected [51]. Whether continued application of intermittent fasting intervals would
translate into a clinical benefit remains unclear. RCTs comparing intermittent versus
continuous feeding have shown mixed results [52, 53]. However, most RCTs were
relatively small, and the fasting interval in these studies (generally only 4 to 6 h) may
have been too short to impact the outcome beneficially [41].
41]. However, the ideal duration of fasting that is needed to
Development and Validation of Tools to Guide Individualized Nutritional Support
Future studies should investigate whether nutritional support, preferably guided by
markers of nutritional need and feeding responsiveness, improves outcome. In
contrast to RCTs in ICU patients, an RCT in hospitalized non-critically ill patients

90 C. Lauwers et al.
showed that enhanced nutritional support improved outcome [54]. Yet, translation of
these results into the ICU setting is difficult, as most patients were able to receive
oral feeding in this study. As anabolic resistance and the need for active repair
processes are presumably dynamic over time and variable between patients, there is
a need for validated biomarkers or prediction tools that can predict and monitor
feeding responsiveness, and detect under- and overfeeding before overt symptoms
28, 5
occur, which needs further study [
there may be a role of indirect calorimetry to guide energy dosing, which also needs
further study. Likewise, the ideal ratio of carbohydrate versus lipid calories remains
to be studied in large RCTs.
5]. In patients who are feeding-responsive,
Implications for Clinical Practice
In the absence of a biomarker or monitor that can adequately predict or document the
response to artificial nutrition, it remains unclear how to optimally titrate nutritional
intake in individual patients over time. Although early enhanced artificial feeding
did not benefit critically ill patients, prolonged underfeeding likely comes at a price.
In patients unable to eat, it seems reasonable to start with low-dose enteral nutrition
within 48 h, as recommended by European guidelines [
increased gradually up to target, or low-dose trophic enteral nutrition can be considered in the first week. In case of enteral feeding intolerance or a contraindication
to enteral nutrition, parenteral nutrition should be withheld, and low intake should be
tolerated up to 1 week after ICU admission [49]. Throughout ICU stay, sufficient
micronutrient intake should be ensured, which may imply parenteral administration
in case of no or only minimal enteral intake [49]. Especially in patients with
prolonged low intake before ICU admission and in patients with other risk factors
of deficiencies, early parenteral administration of vitamins and trace elements should
be considered [56]. Since commercial enteral nutrition formulae contain
micronutrients, parenteral vitamins and trace elements can usually be stopped
when the feeding target is almost reached by enteral or oral nutrition. When a patient
develops refeeding hypophosphatemia, it seems prudent to temporarily restrict
macronutrient intake, while correcting micronutrient and electrolyte deficiencies,
to prevent potentially lethal complications of refeeding syndrome [17, 18].
there
is no benefit of using measured energy targets in the first week of critical
illness, the potential role of indirect calorimetry in prolonged critically ill patients
and in patients recovering from critical illness remains unclear.
49]. Enteral nutrition can be
While
Conclusion
Recent large RCTs have shown that early full nutritional support to critically ill
patients induced dose-dependent harm, regardless of the feeding route. Currently, no
validated nutritional risk scores or biomarkers identify patients who benefit from

8 The Energy Intake: How Much, and at What Time? 91
early enhanced nutritional support. The absence of benefit of early full nutritional
support has been attributed to anabolic resistance and suppression of fasting-induced
recovery pathways, including autophagy and ketogenesis. This opens perspectives
for intermittent feeding/fasting strategies, ketone supplementation, and ketogenic
diets. The time point when anabolic resistance switches into feeding responsiveness
is likely variable, cannot be monitored
or predicted, and requires further study. In the
absence of such a monitor, the value of indirect calorimetry remains obscure,
especially in the acute phase of critical illness.
References
1. Dvir D, Cohen J, Singer P. Computerized energy balance and complications in critically ill
patients: an observational study. Clin Nutr. 2006;25(1):37–44.
2. Alberda C, Gramlich L, Jones N, Jeejeebhoy K, Day AG, Dhaliwal R, et al. The relationship
between nutritional intake and clinical outcomes in critically ill patients: results of an international multicenter observational study. Intensive Care Med. 2009;35(10):1728–37.
3. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, et al. Early versus
late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365(6):506–17.
4. Fivez T, Kerklaan D, Mesotten D, Verbruggen S, Wouters PJ, Vanhorebeek I, et al. Early versus
late parenteral nutrition in critically ill children. N Engl J Med. 2016;374(12):1111–22.
5. Reignier J, Plantefeve G, Mira J-P, Argaud L, Asfar P, Aissaoui N, et al. Low versus standard
calorie and protein feeding in ventilated adults with shock: a randomised, controlled,
multicentre, open-label, parallel-group trial (NUTRIREA-3). Lancet Respir Med. 2023;11(7):
602–12.
6. Verstraete S, Verbruggen SC, Hordijk JA, Vanhorebeek I, Dulfer K, Güiza F, et al. Long-term
developmental effects of withholding parenteral nutrition for 1 week in the paediatric intensive
care unit: a 2-year follow-up of the PEPaNIC international, randomised, controlled trial. Lancet
Respir Med. 2019;7(2):141–53.
7. Jacobs A, Dulfer K, Eveleens RD, Hordijk J, Van Cleemput H, Verlinden I, et al. Long-term
developmental effect of withholding parenteral nutrition in paediatric intensive care units: a
4-year follow-up of the PEPaNIC randomised controlled trial. Lancet Child Adolesc Health.
2020;4(7):503–14.
8. Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M, et al. Initial trophic vs
full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA.
2012;307(8):795–803.
9. Arabi YM, Aldawood AS, Haddad SH, Al-Dorzi HM, Tamim HM, Jones G, et al. Permissive
underfeeding or standard enteral feeding in critically ill adults. N Engl J Med. 2015;372(25):
2398–408.
10. Chapman M, Peake SL, Bellomo R, Davies A, Deane A, Horowitz M, et al. Energy-dense
versus routine enteral nutrition in the critically ill. N Engl J Med. 2018;379(19):1823–34.
11. Harvey SE, Parrott F, Harrison DA, Bear DE, Segaran E, Beale R, et al. Trial of the route of
early nutritional support in critically ill adults. N Engl J Med. 2014;371(18):1673–84.
12. Reignier J, Boisramé-Helms J, Brisard L, Lascarrou JB, Ait Hssain A, Anguel N, et al. Enteral
versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled,
multicentre, open-label, parallel-group study (NUTRIREA-2). Lancet. 2018;391(10116):
133–43.
13. Casaer MP, Wilmer A, Hermans G, Wouters PJ, Mesotten D, Van den Berghe G. Role of
disease and macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis.
Am J Respir Crit Care Med. 2013;187(3):247–55.

92 C. Lauwers et al.
14. Vanhorebeek I, Verbruggen S, Casaer MP, Gunst J, Wouters PJ, Hanot J, et al. Effect of early
supplemental parenteral nutrition in the paediatric ICU: a preplanned observational study of
post-randomisation treatments in the PEPaNIC trial. Lancet Respir Med. 2017;5(6):475–83.
15. Casaer MP, Bellomo R. Micronutrient deficiency in critical illness: an invisible foe? Intensive
Care Med. 2019;45(8):1136–9.
16. Vankrunkelsven W, Gunst J, Amrein K, Bear DE, Berger MM, Christopher KB, et al. Monitoring and parenteral administration of micronutrients, phosphate and magnesium in critically ill
patients: the VITA-TRACE survey. Clin Nutr. 2020;40(2):590–9.
17. Doig GS, Simpson F, Heighes PT, Bellomo R, Chesher D, Caterson ID, et al. Restricted versus
continued standard caloric intake during the management of refeeding syndrome in critically ill
adults: a randomised, parallel-group, multicentre, single-blind controlled trial. Lancet Respir
Med. 2015;3(12):943–52.
18. Olthof LE, Koekkoek WACK, van Setten C, Kars JCN, van Blokland D, van Zanten ARH.
Impact of caloric intake in critically ill patients with, and without, refeeding syndrome: a
retrospective study. Clin Nutr. 2018;37(5):1609–17.
19. da Silva JSV, Seres DS, Sabino K, Adams SC, Berdahl GJ, Citty SW, et al. ASPEN consensus
recommendations for refeeding syndrome. Nutr Clin Pract. 2020;35(2):178–95.
20. Adika E, Jia R, Li J, Seres D, Freedberg DE. Evaluation of the ASPEN guidelines for refeeding
syndrome among hospitalized patients receiving enteral nutrition: a retrospective cohort study.
JPEN J Parenter Enteral Nutr. 2022;46(8):1859–66.
21. Eveleens RD, Witjes BCM, Casaer MP, Vanhorebeek I, Guerra GG, Veldscholte K, et al.
Supplementation of vitamins, trace elements and electrolytes in the PEPaNIC randomised
controlled trial: composition and preparation of the prescription. Clin Nutr ESPEN. 2021;42:
244–51.
22. Hoffer LJ, Bistrian BR. Nutrition in critical illness: a current conundrum. F1000Res. 2016;5:
2531.
23. Felbinger TW, Weigand MA, Mayer K. Early or late parenteral nutrition in critically ill adults.
N Engl J Med. 2011;365(19):1839; author reply 41–2.
24. O’Leary MJ, Ferrie S. Early or late parenteral nutrition in critically ill adults. N Engl J Med.
2011;365(19):1839–40; author reply 41–2.
25. Oshima T, Berger MM, De Waele E, Guttormsen AB, Heidegger CP, Hiesmayr M, et al.
Indirect calorimetry in nutritional therapy. A position paper by the ICALIC study group. Clin
Nutr. 2017;36(3):651–62.
26. Gunst J, Casaer MP, Preiser JC, Reignier J, van den Berghe G. Toward nutrition improving
outcome of critically ill patients: how to interpret recent feeding RCTs? Crit Care. 2023;27(1):
43.
27. van Puffelen E, Hulst JM, Vanhorebeek I, Dulfer K, Van den Berghe G, Verbruggen S, et al.
Outcomes of delaying parenteral nutrition for 1 week vs initiation within 24 hours among
undernourished children in pediatric intensive care: a subanalysis of the PEPaNIC randomized
clinical trial. JAMA Netw Open. 2018;1(5):e182668.
28. Arabi YM, Aldawood AS, Al-Dorzi HM, Tamim HM, Haddad SH, Jones G, et al. Permissive
underfeeding or standard enteral feeding in high and low nutritional risk critically ill adults:
post-hoc analysis of the PermiT trial. Am J Respir Crit Care Med. 2016;195(5):652–62.
29. Jensen GL, Cederholm T, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM
criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition
community. JPEN J Parenter Enteral Nutr. 2019;43(1):32–40.
30. Heyland DK, Patel J, Compher C, Rice TW, Bear DE, Lee ZY, et al. The effect of higher protein
dosing in critically ill patients with high nutritional risk (EFFORT protein): an international,
multicentre, pragmatic, registry-based randomised trial. Lancet. 2023;401(10376):568–76.
Doig GS,
31.
amino acid therapy for kidney function in critically ill patients: a randomized controlled trial.
Intensive Care Med. 2015;41(7):1197–208.
Simpson F, Bellomo R, Heighes PT, Sweetman EA, Chesher D, et al. Intravenous

8 The Energy Intake: How Much, and at What Time? 93
32. Singer P, Anbar R, Cohen J, Shapiro H, Shalita-Chesner M, Lev S, et al. The tight calorie
control study (TICACOS): a prospective, randomized, controlled pilot study of nutritional
support in critically ill patients. Intensive Care Med. 2011;37(4):601–9.
33. Singer P, De Waele E, Sanchez C, Ruiz Santana S, Montejo
international: a multi-center, randomized, prospective controlled study comparing tight calorie
control versus Liberal calorie administration study. Clin Nutr. 2021;40(2):380–7.
34. Casaer MP, Van den Berghe G, Gunst J. Indirect calorimetry: a faithful guide for nutrition
therapy, or a fascinating research tool? Clin Nutr. 2021;40(2):651.
35. Chapple LS, Kouw IWK, Summers MJ, Weinel LM, Gluck S, Raith E, et al. Muscle protein
synthesis after protein administration in critical illness. Am J Respir Crit Care Med. 2022;206
(6):740–9.
36. Hermans G, Casaer MP, Clerckx B, Guiza F, Vanhullebusch T, Derde S, et al. Effect of
tolerating macronutrient deficit on the development of intensive-care unit acquired weakness:
a subanalysis of the EPaNIC trial. Lancet Respir Med. 2013;1(8):621–9.
37. Gunst J, Vanhorebeek I, Casaer MP, Hermans G, Wouters PJ, Dubois J, et al. Impact of early
parenteral nutrition on metabolism and kidney injury. J Am Soc Nephrol. 2013;24(6):
995–1005.
38. Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, et al. A randomized trial
of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013;368(16):1489–97.
39. Allingstrup MJ, Kondrup J, Wiis J, Claudius C, Pedersen UG, Hein-Rasmussen R, et al. Early
goal-directed nutrition versus standard of care in adult intensive care patients: the single-centre,
randomised, outcome assessor-blinded EAT-ICU trial. Intensive Care Med. 2017;43(11):
1637–47.
40. Tappy L, Schwarz JM, Schneiter P, Cayeux C, Revelly JP, Fagerquist CK, et al. Effects of
isoenergetic glucose-based or lipid-based parenteral nutrition on glucose metabolism, de novo
lipogenesis, and respiratory gas exchanges in critically ill patients. Crit Care Med. 1998;26(5):
860–7.
41. Gunst J, Casaer MP, Langouche L, Van den Berghe G. Role of ketones, ketogenic diets and
intermittent fasting in ICU. Curr Opin Crit Care. 2021;27(4):385–9.
42. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):
728–41.
43. Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383(16):1564–76.
44. Gunst J. Recovery from critical illness-induced organ failure: the role of autophagy. Crit Care.
2017;21(1):209.
45. Derde S, Vanhorebeek I, Guiza F, Derese I, Gunst J, Fahrenkrog B, et al. Early parenteral
nutrition evokes a phenotype of autophagy deficiency in liver and skeletal muscle of critically ill
rabbits. Endocrinology. 2012;153(5):2267–76.
46. De Bruyn A, Gunst J, Goossens C, Vander Perre S, Guerra GG, Verbruggen S, et al. Effect of
withholding early parenteral nutrition in PICU on ketogenesis as potential mediator of its
outcome benefit. Crit Care. 2020;24(1):536.
47. De Bruyn A, Langouche L, Vander Perre S, Gunst J, Van den Berghe G. Impact of withholding
early parenteral nutrition in adult critically ill patients on ketogenesis in relation to outcome. Crit
Care. 2021;25(1):102.
48. Goossens C, Weckx R, Derde S, Dufour T, Vander Perre S, Pauwels L, et al. Adipose tissue
protects against sepsis-induced muscle weakness in mice: from lipolysis to ketones. Crit Care.
2019;23(1):236.
49. Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al. ESPEN guideline
on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48–79.
50. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J
Med. 2019;381(26):2541–51.
51.
Van Dyck
fasting-mimicking diet for critically ill patients: the pilot randomized crossover ICU-FM-1
study. Crit Care. 2020;24(1):249.
L, Vanhorebeek I, Wilmer A, Schrijvers A, Derese I, Mebis L, et al. Towards a
JC, Laterre PF, et al. TICACOS

94 C. Lauwers et al.
52. Van Dyck L, Casaer MP. Intermittent or continuous feeding: any difference during the
first week? Curr Opin Crit Care. 2019;25(4):356–62.
53. McNelly AS, Bear DE, Connolly BA, Arbane G, Allum L, Tarbhai A, et al. Effect of
intermittent or continuous feed on muscle wasting in critical illness: a phase 2 clinical trial.
Chest. 2020;158(1):183–94.
54. Schuetz P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, et al. Individualised nutritional
support in medical inpatients at nutritional risk: a randomised clinical trial. Lancet. 2019;393
(10188):2312–21.
55. Van Dyck L, Gunst J, Casaer MP, Peeters B, Derese I, Wouters PJ, et al. The clinical potential
of GDF15 as a “ready-to-feed indicator” for critically ill adults. Crit Care. 2020;24(1):557.
56.
Berger MM,
micronutrient guideline. Clin Nutr. 2022;41(6):1357–424.
Shenkin A, Schweinlin A, Amrein K, Augsburger M, Biesalski HK, et al. ESPEN

Chapter 9
Protein Requirements: Refocusing
on an Essential Nutrient
Emmanuel Pardo and Jean-Charles Preiser
Introduction
The attention towards the long-term consequences of critical illness and a stay in an
intensive care unit (ICU) has increased in recent years, coinciding with advancements in medical therapy that have led to an improved survival rate. Specifically,
muscle weakness acquired in the ICU is associated with a poor outcome [1, 2]. This
ion is characterized by qualitative and quantitative muscle alteration second-
condit
ary to exacerbated catabolism [3–5]. Its consequences may persist over time and
const
itute long-term functional and quality of life impairments [6, 7]. The introduc-
of early nutritional support has been advised by international guidelines to limit
tion
energy and particularly protein debt in critically ill patients in order to potentially
mitigate muscle loss [8–10]. However, the current level of evidence remains limited
and
the risk-to-benefit ratio of high protein intakes is unknown [11]. The prescription
of protein intake should follow a careful timing and amount at each phase of the
critical illness to avoid the development or further deterioration of adverse effects,
including renal impairment.
Supplementary Information The online version contains supplementary material available at
https://doi.org/10.1007/978-3-031-66541-7_9.
E. Pardo
Département d’Anesthésie-Réanimation, Sorbonne Université, GRC 29, AP-HP, DMU
DREAM, Hôpital Saint-Antoine, Assistance publique-hôpitaux de Paris, Paris, France
e-mail: emmanuel.pardo@aphp.fr
J.-C. Preiser (
Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels,
Belgium
e-mail: jean-charles.preiser@erasme.ulb.ac.be
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2024
A.
Cotoia et al. (eds.), Nutrition, Metabolism and Kidney Support,
https://doi.org/10.1007/978-3-031-66541-7_9
✉)
95
Соседние файлы в папке Библиотека им академика М.И. Перельмана
